Cargando…

Budd-Chiari Syndrome: Long term success via hepatic decompression using transjugular intrahepatic porto-systemic shunt

BACKGROUND: Budd-Chiari syndrome (BCS) generally implies thrombosis of the hepatic veins and/or the intrahepatic or suprahepatic inferior vena cava. Treatment depends on the underlying cause, the anatomic location, the extent of the thrombotic process and the functional capacity of the liver. It can...

Descripción completa

Detalles Bibliográficos
Autores principales: Zahn, Alexandra, Gotthardt, Daniel, Weiss, Karl Heinz, Richter, Götz, Schmidt, Jan, Stremmel, Wolfgang, Sauer, Peter
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2838758/
https://www.ncbi.nlm.nih.gov/pubmed/20193077
http://dx.doi.org/10.1186/1471-230X-10-25
_version_ 1782178881138065408
author Zahn, Alexandra
Gotthardt, Daniel
Weiss, Karl Heinz
Richter, Götz
Schmidt, Jan
Stremmel, Wolfgang
Sauer, Peter
author_facet Zahn, Alexandra
Gotthardt, Daniel
Weiss, Karl Heinz
Richter, Götz
Schmidt, Jan
Stremmel, Wolfgang
Sauer, Peter
author_sort Zahn, Alexandra
collection PubMed
description BACKGROUND: Budd-Chiari syndrome (BCS) generally implies thrombosis of the hepatic veins and/or the intrahepatic or suprahepatic inferior vena cava. Treatment depends on the underlying cause, the anatomic location, the extent of the thrombotic process and the functional capacity of the liver. It can be divided into medical treatment including anticoagulation and thrombolysis, radiological procedures such as angioplasty and transjugular intrahepatic porto-systemic shunt (TIPS) and surgical interventions including orthotopic liver transplantation (OLT). Controlled trials or reports on larger cohorts are limited due to rare disease frequency. The aim of this study was to report our single centre long term results of patients with BCS receiving one of three treatment options i.e. medication only, TIPS or OLT on an individually based decision of our local expert group. METHODS: 20 patients with acute, subacute or chronic BCS were treated between 1988 and 2008. Clinical records were analysed with respect to underlying disease, therapeutic interventions, complications and overall outcome. RESULTS: 16 women and 4 men with a mean age of 34 ± 12 years (range: 14-60 years) at time of diagnosis were included. Myeloproliferative disorders or a plasmatic coagulopathy were identified as underlying disease in 13 patients, in the other patients the cause of BCS remained unclear. 12 patients presented with an acute BCS, 8 with a subacute or chronic disease. 13 patients underwent TIPS, 4 patients OLT as initial therapy, 2 patients required only symptomatic therapy, and one patient died from liver failure before any specific treatment could be initiated. Eleven of 13 TIPS patients required 2.5 ± 2.4 revisions (range: 0-8). One patient died from his underlying hematologic disease. The residual 12 patients still have stable liver function not requiring OLT. All 4 patients who underwent OLT as initial treatment, required re-OLT due to thrombembolic complications of the graft. Survival in the TIPS group was 92.3% and in the OLT group 75% during a median follow-up of 4 and 11.5 years, respectively. CONCLUSION: Our results confirm the role of TIPS in the management of patients with acute, subacute and chronic BCS. The limited number of patients with OLT does not allow to draw a meaningful conclusion. However, the underlying disease may generate major complications, a reason why OLT should be limited to patients who cannot be managed by TIPS.
format Text
id pubmed-2838758
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-28387582010-03-16 Budd-Chiari Syndrome: Long term success via hepatic decompression using transjugular intrahepatic porto-systemic shunt Zahn, Alexandra Gotthardt, Daniel Weiss, Karl Heinz Richter, Götz Schmidt, Jan Stremmel, Wolfgang Sauer, Peter BMC Gastroenterol Research Article BACKGROUND: Budd-Chiari syndrome (BCS) generally implies thrombosis of the hepatic veins and/or the intrahepatic or suprahepatic inferior vena cava. Treatment depends on the underlying cause, the anatomic location, the extent of the thrombotic process and the functional capacity of the liver. It can be divided into medical treatment including anticoagulation and thrombolysis, radiological procedures such as angioplasty and transjugular intrahepatic porto-systemic shunt (TIPS) and surgical interventions including orthotopic liver transplantation (OLT). Controlled trials or reports on larger cohorts are limited due to rare disease frequency. The aim of this study was to report our single centre long term results of patients with BCS receiving one of three treatment options i.e. medication only, TIPS or OLT on an individually based decision of our local expert group. METHODS: 20 patients with acute, subacute or chronic BCS were treated between 1988 and 2008. Clinical records were analysed with respect to underlying disease, therapeutic interventions, complications and overall outcome. RESULTS: 16 women and 4 men with a mean age of 34 ± 12 years (range: 14-60 years) at time of diagnosis were included. Myeloproliferative disorders or a plasmatic coagulopathy were identified as underlying disease in 13 patients, in the other patients the cause of BCS remained unclear. 12 patients presented with an acute BCS, 8 with a subacute or chronic disease. 13 patients underwent TIPS, 4 patients OLT as initial therapy, 2 patients required only symptomatic therapy, and one patient died from liver failure before any specific treatment could be initiated. Eleven of 13 TIPS patients required 2.5 ± 2.4 revisions (range: 0-8). One patient died from his underlying hematologic disease. The residual 12 patients still have stable liver function not requiring OLT. All 4 patients who underwent OLT as initial treatment, required re-OLT due to thrombembolic complications of the graft. Survival in the TIPS group was 92.3% and in the OLT group 75% during a median follow-up of 4 and 11.5 years, respectively. CONCLUSION: Our results confirm the role of TIPS in the management of patients with acute, subacute and chronic BCS. The limited number of patients with OLT does not allow to draw a meaningful conclusion. However, the underlying disease may generate major complications, a reason why OLT should be limited to patients who cannot be managed by TIPS. BioMed Central 2010-03-01 /pmc/articles/PMC2838758/ /pubmed/20193077 http://dx.doi.org/10.1186/1471-230X-10-25 Text en Copyright ©2010 Zahn et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Zahn, Alexandra
Gotthardt, Daniel
Weiss, Karl Heinz
Richter, Götz
Schmidt, Jan
Stremmel, Wolfgang
Sauer, Peter
Budd-Chiari Syndrome: Long term success via hepatic decompression using transjugular intrahepatic porto-systemic shunt
title Budd-Chiari Syndrome: Long term success via hepatic decompression using transjugular intrahepatic porto-systemic shunt
title_full Budd-Chiari Syndrome: Long term success via hepatic decompression using transjugular intrahepatic porto-systemic shunt
title_fullStr Budd-Chiari Syndrome: Long term success via hepatic decompression using transjugular intrahepatic porto-systemic shunt
title_full_unstemmed Budd-Chiari Syndrome: Long term success via hepatic decompression using transjugular intrahepatic porto-systemic shunt
title_short Budd-Chiari Syndrome: Long term success via hepatic decompression using transjugular intrahepatic porto-systemic shunt
title_sort budd-chiari syndrome: long term success via hepatic decompression using transjugular intrahepatic porto-systemic shunt
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2838758/
https://www.ncbi.nlm.nih.gov/pubmed/20193077
http://dx.doi.org/10.1186/1471-230X-10-25
work_keys_str_mv AT zahnalexandra buddchiarisyndromelongtermsuccessviahepaticdecompressionusingtransjugularintrahepaticportosystemicshunt
AT gotthardtdaniel buddchiarisyndromelongtermsuccessviahepaticdecompressionusingtransjugularintrahepaticportosystemicshunt
AT weisskarlheinz buddchiarisyndromelongtermsuccessviahepaticdecompressionusingtransjugularintrahepaticportosystemicshunt
AT richtergotz buddchiarisyndromelongtermsuccessviahepaticdecompressionusingtransjugularintrahepaticportosystemicshunt
AT schmidtjan buddchiarisyndromelongtermsuccessviahepaticdecompressionusingtransjugularintrahepaticportosystemicshunt
AT stremmelwolfgang buddchiarisyndromelongtermsuccessviahepaticdecompressionusingtransjugularintrahepaticportosystemicshunt
AT sauerpeter buddchiarisyndromelongtermsuccessviahepaticdecompressionusingtransjugularintrahepaticportosystemicshunt